Meningococcal vaccines: Current state and future outlook

Pathologie Biologie

Volumn 63, Issue 3, 2015, Pages 144-151

  Leca, M ^a   Bornet, C ^b   Montana, M ^c,d   Curti, C ^c,d   Vanelle, P ^c,d  

^a HÔPITAL NORD   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Bexsero ; Neisseria meningitidis; Reverse vaccinology; Trumemba ; Vaccine

Indexed keywords

FACTOR H BINDING PROTEIN; MEMBRANE PROTEIN; MENINGOCOCCUS VACCINE; NEISSERIA ADHESIN A; NEISSERIA HEPARIN BINDING ANTIGEN; PHENACETIN; PLACEBO; UNCLASSIFIED DRUG; 4CMENB VACCINE; BACTERIAL ANTIGEN;

AUSTRALIA; BACTERIAL TRANSMISSION; CHLAMYDOPHILA PNEUMONIAE; CLINICAL STUDY; CRYING; DIARRHEA; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; EATING HABIT; ERYTHEMA; EUROPE; FEBRILE CONVULSION; FEVER; HEADACHE; HUMAN; IDIOPATHIC DISEASE; IMMUNITY LOSS; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE INDURATION; IRRITABILITY; JUVENILE RHEUMATOID ARTHRITIS; LICENSING; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTILOCUS SEQUENCE TYPING; NASOPHARYNGEAL CARRIAGE; NONHUMAN; RASH; REVIEW; SIDE EFFECT; SOMNOLENCE; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; UNITED STATES; VACCINATION; VOMITING; BACTERIAL CAPSULE; CLASSIFICATION; COST BENEFIT ANALYSIS; ECONOMICS; FORECASTING; GENETIC SELECTION; GENETICS; HEALTH; IMMUNOLOGY; ISOLATION AND PURIFICATION; MENINGOCOCCAL INFECTIONS; MICROBIOLOGY; NASOPHARYNX; NEISSERIA MENINGITIDIS; PATHOGENICITY; VIRULENCE;

ANTIGENS, BACTERIAL; AUSTRALIA; BACTERIAL CAPSULES; COST-BENEFIT ANALYSIS; EUROPE; FORECASTING; GLOBAL HEALTH; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NASOPHARYNX; NEISSERIA MENINGITIDIS; NEISSERIA MENINGITIDIS, SEROGROUP B; SELECTION, GENETIC; UNITED STATES; VACCINATION; VIRULENCE;

EID: 84930485576     PISSN: 03698114     EISSN: 17683114     Source Type: Journal    
DOI: 10.1016/j.patbio.2015.04.003     Document Type: Review

References (100)

1. Turner N.M., York D.G., Petousis-Harris H.A. The use and misuse of media headlines: lessons from the MeNZB immunisation campaign. N Z Med J 2009, 122:22-27.
2. Strelow V.L., Vidal J.E. Invasive meningococcal disease. Arq Neuropsiquiatr 2013, 71:653-658.
3. Stephens D.S. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine 2009, 27:B71-B77.
4. Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec 2011, 86:521-539.
5. McIntyre P.B., O'Brien K.L., Greenwood B., Van De Beek D. Effect of vaccines on bacterial meningitis worldwide. Lancet 2012, 380:1703-1711.
6. Roderick M., Finn A. Advances towards the prevention of meningococcal B disease: a multidimensional story. J Infect 2014, 68:S76-S82.
7. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737-1746.
8. Stephens D.S., Greenwood B., Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007, 369:2196-2210.
9. Swartley J.S., Marfin A.A., Edupuganti S., Liu L.J., Cieslak P., Perkins B., et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci U S A 1997, 94:271-276.
10. Yogev R., Tan T. Meningococcal disease: the advances and challenges of meningococcal disease prevention. Hum Vaccin 2011, 7:828-837.
11. Racloz V.N., Luiz S.J. The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC Infect Dis 2010, 10:175.
12. Kaaijk P., van der Ende A., Luytjes W. Routine vaccination against MenB: considerations for implementation. Hum Vaccin Immunother 2013, 10:310-316.
13. Vipond C., Care R., Feavers I.M. History of meningococcal vaccines and their serological correlates of protection. Vaccine 2012, 30:B10-B17.
14. Halperin S.A., Bettinger J.A., Greenwood B., Harrison L.H., Jelfs J., Ladhani S.N., et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine 2012, 30:B26-B36.
15. Djingarey M.H., Barry R., Bonkoungou M., Tiendrebeogo S., Sebgo R., Kandolo D., et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine 2012, 30:B40-B45.
16. Cohn A.C., MacNeil J.R., Clark T.A., Ortega-Sanchez I.R., Briere E.Z., Meissner H.C., et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013, 62(RR-2):1-28.
17. Christensen H., May M., Bowen L., Trotter C.L. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10:853-861.
18. INVS. Les infections invasives à méningocoque en France en 2011. Available from: URL: [French], 2014. http://www.invs.sante.fr/Dossiers-thematiques/Maladies-infectieuses/Maladies-a-prevention-vaccinale/Infections-invasives-a-meningocoques/Donnees-epidemiologiques/Les-infections-invasives-a-meningocoque-en-France-en-2011.
19. MacLennan J., Kafatos G., Neal K., Andrews N., Cameron J.C., Roberts R., et al. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis 2006, 12:950-957.
20. Pace D., Pollard A.J. Meningococcal disease: clinical presentation and sequelae. Vaccine 2012, 30:B3-B9.
21. Maiden M.C., Frosch M. Can we, should we, eradicate the meningococcus?. Vaccine 2012, 30:B52-B56.
22. Caron F., du Châtelet I.P., Leroy J.P., Ruckly C., Blanchard M., Bohic N., et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis 2011, 11:455-463.
23. Borrow R., Balmer P., Miller E. Meningococcal surrogates of protection - serum bactericidal antibody activity. Vaccine 2005, 23:2222-2227.
24. Holst J., Martin D., Arnold R., Huergo C.C., Oster P., O'Hallahan J., et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009, 27:B3-B12.
25. Finne J., Leinonen M., Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983, 2:355-357.
26. Sacchi C.T., Whitney A.M., Popovic T., Beall D.S., Reeves M.W., Plikaytis B.D., et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J Infect Dis 2000, 182:1169-1176.
27. Feavers I.M., Pizza M. Meningococcal protein antigens and vaccines. Vaccine 2009, 27:B42-B50.
28. de Moraes J.C., Perkins B.A., Camargo M.C., Hidalgo N.T., Barbosa H.A., Sacchi C.T., et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992, 340:1074-1078.
29. Boslego J., Garcia J., Cruz C., Zollinger W., Brandt B., Ruiz S., et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 1995, 13:821-829.
30. Sierra G.V., Campa H.C., Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH 1991, 14:195-210.
31. Bjune G., Hoiby E.A., Gronnesby J.K., Arnesen O., Fredriksen J.H., Halstensen A., et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991, 338:1093-1096.
32. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005, 23:2191-2196.
33. Oster P., O'Hallahan J., Aaberge I., Tilman S., Ypma E., Martin D. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine 2007, 25:3075-3079.
34. Caron F., Delbos V., Houivet E., Deghmane A.E., Leroy J.P., Hong E., et al. Evolution of immune response against Neisseria meningitidis B:14:P1.7,16 before and after the outer membrane vesicle vaccine MenBvac. Vaccine 2012, 30:5059-5062.
35. Holst J., Feiring B., Naess L.M., Norheim G., Kristiansen P., Høiby E.A., et al. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005, 23:2202-2205.
36. Tappero J.W., Lagos R., Ballesteros A.M., Plikaytis B., Williams D., Dykes J., et al. Immunogenicity of 2 serogroup B outer membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999, 281:1520-1527.
37. Schubert-Unkmeir A., Christodoulides M. Genome-based bacterial vaccines: current state and future outlook. BioDrugs 2013, 27:419-430.
38. Caesar N.M., Myers K.A., Fan X. Neisseria meningitidis serogroup B vaccine development. Microb Pathog 2013, 57:33-40.
39. Nedelec J., Boucraut J., Garnier J.M., Bernard D., Rougon G. Evidence for autoimmune antibodies directed against embryonic neural cell adhesion molecules (N-CAM) in patients with group B meningitis. J Neuroimmunol 1990, 29:49-56.
40. Bansal V., Kumar M., Dalela M., Brahmne H.G., Singh H. Evaluation of synergistic effect of biodegradable polymeric nanoparticles and aluminum based adjuvant for improving vaccine efficacy. Int J Pharm 2014, 471:377-384.
41. Bruge J., Bouveret-Le Cam N., Danve B., Rougon G., Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 2004, 22:1087-1096.
42. Serruto D., Adu-Bobie J., Capecchi B., Rappuoli R., Pizza M., Masignani V. Biotechnology and vaccines: application of functional genomics to Neisseria meningitidis and other bacterial pathogens. J Biotechnol 2004, 113:15-32.
43. Danzig L. Reverse vaccinology - in search of a genome-derived meningococcal vaccine. Vaccine 2006, 24(Suppl. 2):11-12.
44. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 2001, 19:2688-2691.
45. Serruto D., Bottomley M.J., Ram S., Giuliani M.M., Rappuoli R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 2012, 30:B87-B97.
46. Kelly D.F., Rappuoli R. Reverse vaccinology and vaccines for serogroup B Neisseria meningitidis. Adv Exp Med Biol 2005, 568:217-223.
47. Giuliani M.M., Adu-Bobie J., Comanducci M., Aricò B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006, 103:10834-10839.
48. Vesikari T., Esposito S., Prymula R., Ypma E., Kohl I., Toneatto D., et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013, 381:825-835.
49. Murphy E., Andrew L., Lee K.L., Dilts D.A., Nunez L., Fink P.S., et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009, 200:379-389.
50. Lucidarme J., Comanducci M., Findlow J., Gray S.J., Kaczmarski E.B., Guiver M., et al. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol 2010, 17:919-929.
51. Comanducci M., Bambini S., Brunelli B., Adu-Bobie J., Aricò B., Capecchi B., et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002, 195:1445-1454.
52. Litt D.J., Savino S., Beddek A., Comanducci M., Sandiford C., Stevens J., et al. Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J Infect Dis 2004, 190:1488-1497.
53. Capecchi B., Adu-Bobie J., Di Marcello F., Ciucchi L., Masignani V., Taddei A., et al. Neisseria meningitidis NadA is a new invasion, which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol 2005, 55:687-698.
54. Serruto D., Spadafina T., Ciucchi L., Lewis L.A., Ram S., Tontini M., et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A 2010, 107:3770-3775.
55. Toneatto D., Ismaili S., Ypma E., Vienken K., Oster P., Dull P. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin 2011, 7:646-653.
56. Giuliani M.M., Biolchi A., Serruto D., Ferlicca F., Vienken K., Oster P., et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 2010, 28:5023-5030.
57. Findlow J., Borrow R., Snape M., Dawson T., Holland A., John T.M., et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010, 51:1127-1137.
58. Gherardi R.K., Coquet M., Cherin P., Authier F.J., Laforêt P., Bélec L., et al. Macrophagic myofasciitis: an emerging entity. Lancet 1998, 352:347-352.
59. Center for Disease Control and prevention. Meningococcal disease. Available from: URL: , 2015. http://www.cdc.gov/meningococcal/outbreaks/vaccine-serogroupb.html.
60. FDA. Trumemba highlights of prescribing informations. Available from: URL: , 2014. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM421139.pdf.
61. Van Alphen L., van den Dobbelsteen G., Meningococcal B. vaccine development and evaluation of efficacy. Hum Vaccin 2008, 4:158-161.
62. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969, 129:1307-1326.
63. Borrow R., Carlone G.M., Rosenstein N., Blake M., Feavers I., Martin D., et al. Neisseria meningitidis group B correlates of protection and assay standardization - international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006, 24:5093-5107.
64. Holst J., Feiring B., Fuglesang J.E., Høiby E.A., Nøkleby H., Aaberge I.S., et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003, 21:734-737.
65. Santolaya M.E., O'Ryan M.L., Valenzuela M.T., Prado V., Vergara R., Muñoz A., et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012, 379:617-624.
66. Haut Conseil de la Santé Publique. Vaccination contre les infections invasives à méningocoque B, place du vaccin Bexsero®. Available from: URL: [French], 2013. http://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=386.
67. Frasch C.E., Borrow R., Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009, 27:B112-B116.
68. Donnelly J., Medini D., Boccadifuoco G., Biolchi A., Ward J., Frasch C., et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 2010, 107:19490-19495.
69. Vogel U., Taha M.K., Vazquez J.A., Findlow J., Claus H., Stefanelli P., et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 2013, 13:416-425.
70. Snape M.D., Medini D., Halperin S.A., DeTora L., Drori J., Moxon E.R. The challenge of post-implementation surveillance for novel meningococcal vaccines. Vaccine 2012, 30:B67-B72.
71. Gill C.J. Novel assessment of a novel meningitis B vaccine. Lancet Infect Dis 2013, 13:381-382.
72. Snape M.D., Philip J., John T.M., Robinson H., Kelly S., Gossger N., et al. Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial. Pediatr Infect Dis J 2013, 32:1116-1121.
73. Bettinger J.A., Scheifele D.W., Halperin S.A., Vaudry W., Findlow J., Borrow R., et al. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine 2013, 32:124-130.
74. Major M., Moss S., Gold R. From genes to vaccine: a breakthrough in the prevention of meningococcal group B disease. Paediatr Child Health 2011, 16:e61-e64.
75. Gossger N., Snape M.D., Yu L.M., Finn A., Bona G., Esposito S., et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012, 307:573-582.
76. Haut Conseil de la Santé Publique. Avis relatif à l'introduction du vaccin Bexsero® dans la campagne de vaccination contre le méningocoque B:14:P1.7,16 dans les départements de Seine-Maritime et de la Somme. Available from: URL: [French], 2013. http://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=373.
77. Marshall H., Clarke M., Sullivan T. Parental and community acceptance of the benefits and risks associated with meningococcal B vaccines. Vaccine 2014, 32:338-344.
78. Prymula R., Siegrist C.A., Chlibek R., Zemlickova H., Vackova M., Smetana J., et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet 2009, 374:1339-1350.
79. Yalçin S.S. Prophylactic paracetamol at the time of infant vaccination reduces the risk of fever, but also reduces antibody response. Evid Based Nurs 2010, 13:76-77.
80. ®): a review of its use in primary and booster vaccination. BioDrugs 2013, 27:263-274.
81. Kramer M.F., Heath M.D. Aluminium in allergen-specific subcutaneous immunotherapy - a German perspective. Vaccine 2014, 32:4140-4148.
82. Tomljenovic L., Shaw C.A. Aluminum vaccine adjuvants: are they safe?. Curr Med Chem 2011, 18:2630-2637.
83. Martinon-Torres F. Immunisation against meningococcus B: the case of Spain. Lancet 2013, 382:1552-1553.
84. Holmes D. UK poised to make decision on 4CMenB vaccine. Lancet Infect Dis 2014, 14:192-193.
85. Stephens D.S., Ahmed R., Orenstein W.A. Vaccines at what price?. Vaccine 2014, 32:1029-1030.
86. Moxon R., Snape M.D. The price of prevention: what now for immunisation against meningococcus B. Lancet 2013, 382:369-370.
87. Christensen H., Hickman M., Edmunds W.J., Trotter C.L. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine 2013, 31:2638-2646.
88. Wang B., Clarke M., Afzali H.H., Marshall H. Community, parental and adolescent awareness and knowledge of meningococcal disease. Vaccine 2014, 32:2042-2049.
89. Vu D.M., Welsch J.A., Zuno-Mitchell P., Dela Cruz J.V., Granoff D.M. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis 2006, 193:821-828.
90. Snape M.D., Saroey P., John T.M., Robinson H., Kelly S., Gossger N., et al. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. CMAJ 2013, 185:E715-E724.
91. Maiden M.C., Spratt B.G. Meningococcal conjugate vaccines: new opportunities and new challenges. Lancet 1999, 354:615-616.
92. Maiden M.C., Stuart J.M., UK Meningococcal Carraige Group Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002, 359:1829-1831.
93. Pinto V.B., Moran E.E., Cruz F., Wang X.M., Fridman A., Zollinger W.D., et al. An experimental outer membrane vesicle vaccine from N.meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups. Vaccine 2011, 29:7752-7758.
94. Bucci C., Lavitola A., Salvatore P., Del Giudice L., Massardo D.R., Bruni C.B., et al. Hypermutation in pathogenic bacteria: frequent phase variation in meningococci is a phenotypic trait of aspecialized mutator biotype. Mol Cell 1999, 3:435-445.
95. Kertesz D.A., Coulthart M.B., Ryan J.A., Johnson W.M., Ashton F.E. Serogroup B, electrophoretic type 15 Neisseria meningitidis in Canada. J Infect Dis 1998, 177:1754-1757.
96. Nair M. Protein conjugate polysaccharide vaccines: challenges in development and global implementation. Indian J Community Med 2012, 37:79-82.
97. Stefanelli P., Fazio C., Neri A., Sofia T., Mastrantonio P. First report of capsule replacement among electrophoretic type 37 Neisseria meningitidis strains in Italy. J Clin Microbiol 2003, 41:5783-5786.
98. Beddek A.J., Li M.S., Kroll J.S., Jordan T.W., Martin D.R. Evidence for capsule switching between carried and disease-causing Neisseria meningitidis strains. Infect Immun 2009, 77:2989-2994.
99. Heyderman R.S., Davenport V., Williams N.A. Mucosal immunity and optimizing protection with meningococcal serogroup B vaccines. Trends Microbiol 2006, 14:120-124.
100. Marshall H.S., Richmond P.C., Nissen M.D., Wouters A., Baber J., Jiang Q., et al. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine 2013, 31:1569-1575.